MRKR · Marker Therapeutics, Inc. · Documents
$1.16
-0.04 (-3.33%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$20.01M
Shares
16.67M
Volume · Oct 20
209.43K
Avg daily vol (3M)
98.63K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Marker Therapeutics announced on October 19, 2026 a $2.6 million FDA Orphan Products Development Grant to advance its lead MAR-T cell therapy, MT-601, in patients with locally advanced unresectable pancreatic cancer, with clinical initiation expected in Q1 2027. | 2026-10-19 | — | |
| 10-Q | — | 2026-08-14 | 2026-06-30 | |
| 10-Q | — | 2026-05-15 | 2026-03-31 | |
| 8-K | — | 2026-05-04 | 2026-05-01 | |
| ARS | — | 2026-03-20 | 2025-12-31 | |
| DEF 14A | — | 2026-03-20 | 2026-05-01 | |
| DEFA14A | — | 2026-03-20 | — | |
| 8-K | — | 2026-03-19 | 2026-03-18 | |
| 10-K | — | 2026-03-18 | 2025-12-31 | |
| PRE 14A | — | 2026-03-10 | 2026-05-01 | |
| 8-K | — | 2026-02-09 | — | |
| 8-K | — | 2025-11-14 | — | |
| 10-Q | — | 2025-11-13 | 2025-09-30 | |
| 8-K | — | 2025-11-05 | 2025-10-31 | |
| 8-K | — | 2025-10-06 | — | |
| 8-K | — | 2025-08-26 | — | |
| 10-Q | — | 2025-08-14 | 2025-06-30 | |
| 8-K | — | 2025-08-12 | 2025-08-07 | |
| 8-K | — | 2025-06-17 | 2025-06-16 | |
| 8-K | — | 2025-06-09 | 2025-06-06 | |
| 8-K | — | 2025-05-20 | — | |
| 10-Q | — | 2025-05-15 | 2025-03-31 | |
| ARS | — | 2025-04-24 | 2024-12-31 | |
| DEF 14A | — | 2025-04-24 | 2025-06-06 | |
| DEFA14A | — | 2025-04-24 | — | |
| 10-K | — | 2025-03-31 | 2024-12-31 | |
| 8-K | — | 2025-03-31 | — | |
| 8-K | — | 2025-03-27 | 2025-03-21 | |
| 8-K/A | — | 2025-03-04 | 2025-02-12 | |
| 8-K | — | 2025-02-19 | 2025-02-12 | |
| DEFA14A | — | 2025-02-04 | — | |
| DEF 14A | — | 2025-02-04 | 2025-03-21 | |
| 8-K | — | 2025-01-30 | 2025-01-24 | |
| PRE 14A | — | 2025-01-13 | 2025-03-21 | |
| S-3 | — | 2025-01-10 | — | |
| 8-K | — | 2024-12-23 | — | |
| 8-K | — | 2024-12-19 | — | |
| 8-K | — | 2024-12-17 | — | |
| S-3 | — | 2024-11-27 | — | |
| 8-K | — | 2024-11-14 | — | |
| 10-Q | — | 2024-11-14 | 2024-09-30 | |
| 10-Q | — | 2024-08-14 | 2024-06-30 | |
| 8-K | — | 2024-08-14 | — | |
| 8-K | — | 2024-08-12 | — | |
| 8-K | — | 2024-06-12 | 2024-06-06 | |
| 8-K | — | 2024-05-15 | — | |
| 10-Q | — | 2024-05-15 | 2024-03-31 | |
| DEF 14A | — | 2024-04-26 | 2024-06-06 | |
| ARS | — | 2024-04-26 | 2023-12-31 | |
| 8-K | — | 2024-04-08 | — |
Showing 1–50 of 142 filings